Approved drugs for multiple sclerosis: the challenge of choice

[1]  J. Lechner-Scott,et al.  Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study , 2017, The Lancet Neurology.

[2]  Xavier Montalban,et al.  Treatment decisions in multiple sclerosis — insights from real-world observational studies , 2017, Nature Reviews Neurology.

[3]  Jeffrey A. Cohen,et al.  Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients , 2016, Neurology.

[4]  G. Salanti,et al.  Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. , 2015, The Cochrane database of systematic reviews.

[5]  Christian Confavreux,et al.  Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial , 2012, The Lancet.

[6]  Jeffrey A. Cohen,et al.  Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial , 2012, The Lancet.

[7]  C. Polman,et al.  Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis , 2011, Multiple sclerosis.

[8]  Georgia Salanti,et al.  Evaluation of networks of randomized trials , 2008, Statistical methods in medical research.

[9]  J. Norrie,et al.  Pragmatic Trials. , 2016, The New England journal of medicine.